Lexaria Bioscience Corp. Logo

Lexaria Bioscience Corp.

Biotech firm with patented technology improving oral drug delivery and absorption.

LEXX | US

Overview

Corporate Details

ISIN(s):
US52886N4060 (+1 more)
LEI:
Country:
United States of America
Address:
100 - 740 MCCURDY ROAD, KELOWNA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lexaria Bioscience Corp. is a biotechnology company focused on its patented drug delivery technology platform, DehydraTECH™. This technology improves the way active pharmaceutical ingredients (APIs) and other bioactive molecules enter the bloodstream through oral delivery. DehydraTECH enhances bio-absorption and has demonstrated superior pharmacokinetics across a broad range of small and large molecules, including GLP-1 peptide drugs. The platform is applicable to various product formats such as tablets, capsules, and oral suspensions. The company's technology is protected by a robust intellectual property portfolio with over 50 patents granted internationally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lexaria Bioscience Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lexaria Bioscience Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lexaria Bioscience Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea
226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America
OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France
ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France
ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway
OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan
4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America
ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America
ONCO
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO

Talk to a Data Expert

Have a question? We'll get back to you promptly.